The German-American cancer research firm Micromet is being taken over by biotech giant Amgen, thus giving it access to Micromet’s promising leukemia therapy.
Amgen said it would pay (Dollor) 1.16 billion for Micromet, founded by a team of German scientists to tap the potential of T-cell therapies to fight cancer.
The company, based in Rockville, Maryland, has developed blinatumomab, a T-cell based treatment for acute lymphoblastic leukemia and possibly non-Hodgkin’s lymphoma
No comments:
Post a Comment